Latest Breaking News On - நோயாளி ஆதரவு ப்ரோக்ர்யாம் - Page 1 : comparemela.com
BeiGene Announces Approval in Canada of BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Mantle Cell Lymphoma
cadillacnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from cadillacnews.com Daily Mail and Mail on Sunday newspapers.
FDA Approves Expanded Indication for Merck s KEYTRUDA® in Locally Advanced Cutaneous Squamous Cell Carcinoma
investingnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investingnews.com Daily Mail and Mail on Sunday newspapers.
May 18, 2021
Manage the Patient Support Program (PSP) for Copaxone Support (Helpline and email address) for new and existing patients, Solus V2 Helpline, assist upon request with other patient support programs or projects to be allocated as and when required by line manager.
Start new patients on Copaxone
Ensure that new patients understand the product and injection techniques in order to solve their queries with regards to the same
Plan quarterly calls / visits to existing Copaxone patients in order to monitor the performance
Contact / visit neurologists at least twice a year to provide feedback on existing Copaxone patients
Compile all necessary information and documentation provided by the neurologists and patients, forward it to the courier houses (Medipost & Pharmacy Direct etc.) for authorisation of Copaxone by the funder
Operator
Good day and welcome to the alboreto pharma first quarter 2021 earnings conference call. [Operator Instructions]
At this time, I would like to turn the conference over to Mr. Paul. Please go ahead, sir.
Paul S. Bavier
Interim President, General Counsel And Secretary
Thank you, operator and good morning everyone. Thank you for joining today s call. This morning, Alberto issued a press release highlighting its recent business accomplishments and reporting its financial results for the first quarter ended March 31 2021. This press release is accessible via the company s website at www dot albireo pharma.com. Before proceeding, we would like to note that management s comments today may include bold looking statements regarding the company s plans and expectations. These statements are being made under the private securities litigation Reform Act of 1995. And they are subject to various risks and uncertainties. Actual results may differ materially due to various important
ADC Therapeutics gibt FDA-Zulassung von ZYNLONTA™ (Loncastuximab-Tesirin-Lpyl) bei rezidiviertem oder refraktärem großzelligem diffusen B-Zell-Lymphom bekannt
boerse-social.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from boerse-social.com Daily Mail and Mail on Sunday newspapers.